Organization
Novartis Corporation
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Novartis Corporation
... past year, the new start oral DMT class share, including Genzyme's Aubagio, Novartis' Gilenya, and Biogen's Tecfidera, has remained stable with the prior audit. Instead, ...
... of bringing safe, effective products to patients," explains Vivianne Arencibia, Global Head, Novartis Quality External Engagement. DIA NOW will enable access to curated content customized ...
... vice president of Global Solutions for LinkedIn; Robert Pelzer, former president of Novartis Corporation; Matthew Ray, founder and managing partner of Portage Point Partners; and ...
... growth. Mavenclad, primarily prescribed to relapsing-remitting MS (RRMS) patients, is competing with Novartis' Gilenya and monoclonal antibody (mAb) DMTs, such as Roche's Ocrevus, Sanofi's Lemtrada, ...
... Ms. Boudreau held a variety of leadership roles with increasing responsibility at Novartis, including serving as the Chief Financial Officer of Novartis Corporation, the U.S. ...
... Donors Genentech, a member of the Roche Group, Bristol-Myers Squibb Company and Novartis. Their support will fund a total of 300 awards through the first ...
... multibillion-dollar sales in the near term. A similar story played out with Novartis's Entresto, a treatment for heart failure that CEO Joseph Jimenez christened a ...
... directors. Prior to joining ARUP, Braendle held multiple leadership roles at Novartis Pharmaceutical Corporation and Schering AG. Most recently, he was senior vice president and ...
... Novartis has announced data from the new post-hoc analyses that underscore the clinical ...
Subscribe now for full coverage on Novartis Corporation
Start My Free Trial